Vasopressin, Vasopressin In Dextrose 5%

For vasodilatory shock. ANDA 213988, held by Dr Reddys. Vasopressin.

As of Nov 15, 2026, ANDA 213988 (Vasopressin, Vasopressin In Dextrose 5%), held by Dr Reddys, was first approved by FDA on May 8, 2024, with 2 approved supplements and 0 published complete response letters.

First approved: May 8, 2024
Review: Standard
Supplements approved: 2
Complete response letters: 0

What It's For

From the FDA-approved label (Indications and Usage)

Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.

Full prescribing information on DailyMed ↗

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 3 submissions below

Date	Submission	Status	Documents
May 8, 2024	Original application	Approved	None posted

Products

2 strengths and forms


Vasopressin20UNITS/ML (20UNITS/ML) · solution;intravenous	Vasopressin	Rx
Vasopressin In Dextrose 5%40UNITS/100ML (0.4UNITS/ML) · solution;intravenous	Vasopressin	Rx

All 3 submissions, including labeling and manufacturing supplements


Jun 3, 2026	Supplement 2Manufacturing	Approved	None posted
Jun 3, 2026	Supplement 3Manufacturing	Approved	None posted
May 8, 2024	Original application	Approved	None posted

Identifiers

Application: ANDA 213988
Drugs@FDA: Overview at FDA
Company: Dr. Reddy's Laboratories

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters